Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

摘要: Thirty-seven eligible patients, median age 59 years (range 37-72) and performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients retroperitoneal lymph nodes 16. Eight of 33 evaluable (24%) achieved a partial remission for 7.5 months (3-11+). An additional 11 had stabilisation disease. The received four cycles docetaxel 1-8) total 156 courses. Dose reduction was necessary 30 cycles; 14 delayed mean days. Haematological toxicity consisted mainly non-cumulative neutropenia, nadir count 0.35 x 10(9) l-1 (0.04-1.64) eight episodes (5%) leucopenic fever; non-haematological toxicities alopecia, mild nausea vomiting allergic manifestations such as skin rash pruritus. There no drug-related deaths. Our data indicate that is an active agent advanced cancer; further clinical investigations seem warranted.